Trials / Completed
CompletedNCT00454805
AZD2171 in Addition to Fulvestrant in Patients With Advanced Breast Cancer.
A Phase II, Double-Blind, Placebo Controlled, Randomized Study to Assess the Efficacy and Safety of AZD2171 in Combination With Fulvestrant vs Fulvestrant Alone in Hormone Sensitive (ER+ve or PgR+ve) Post Menopausal Metastatic Breast Cancer Patients
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 75 (actual)
- Sponsor
- AstraZeneca · Industry
- Sex
- Female
- Age
- 18 Years – 130 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine whether AZD2171 can effectively improve time to tumour progression when added to fulvestrant in patients with advanced hormone sensitive breast cancer who progressed on prior hormonal therapy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | AZD2171 | Oral tablet |
| DRUG | Fulvestrant | intramuscular injection |
Timeline
- Start date
- 2007-03-01
- Primary completion
- 2008-12-01
- Completion
- 2016-04-01
- First posted
- 2007-04-02
- Last updated
- 2016-08-03
- Results posted
- 2012-11-28
Locations
16 sites across 3 countries: United States, Australia, Brazil
Source: ClinicalTrials.gov record NCT00454805. Inclusion in this directory is not an endorsement.